Chennai FMCG maker of Amrutanjan pain balms, Relief congestion rubs, Comfy napkins and Electro+ rehydration drinks/ORS since 1893.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 156 | 213 | 262 | 288 | 286 | 324 | 339 | 367 |
| Borrowings | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Other Liabilities | 44 | 57 | 84 | 70 | 77 | 93 | 88 | 137 |
| Total Liabilities | 205 | 274 | 350 | 362 | 367 | 421 | 432 | 509 |
| AssetsFixed Assets | 26 | 23 | 28 | 49 | 50 | 49 | 49 | 51 |
| CWIP | 0 | 2 | 17 | 1 | 2 | 16 | 26 | 105 |
| Investments | 18 | 18 | 13 | 5 | 0 | 0 | 0 | 3 |
| Other Assets | 161 | 232 | 291 | 307 | 315 | 356 | 357 | 349 |
| Total Assets | 205 | 274 | 350 | 362 | 367 | 421 | 432 | 509 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 21 | 18 | 91 | 52 | 20 | 28 | 51 | 36 |
| Cash from Investing | -11 | -14 | -88 | -36 | -2 | 19 | -31 | -21 |
| Cash from Financing | -7 | -12 | -7 | -17 | -15 | -48 | -13 | -14 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 19 | 16 | 89 | 29 | 11 | 21 | 15 | -19 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (40.0×) and current (26.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 11.9% growth and a 27× exit, ₹538 only delivers your return if you pay ₹412. The price is currently baking in 17% growth.
EPS grows 11.9%/yr for 5 years, then fades to 6% over 2, exits at 27×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 11.9% | 22.41 |
| FY28 | 11.9% | 25.08 |
| FY29 | 11.9% | 28.07 |
| FY30 | 11.9% | 31.41 |
| FY31 | 11.9% | 35.14 |
| FY32 | 8.9% ·fade | 38.29 |
| FY33 | 6.0% ·fade | 40.58 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.